Hodgkin Lymphoma
Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma
Conference Coverage
Childhood Hodgkin survivors have neurocognitive impairment
Clinical Insights
Efforts to close the ‘AYA gap’ in lymphoma
Conference Coverage
Survey quantifies COVID-19’s impact on oncology
Oncologists detail how COVID-19 has impacted care, caregivers, continuing medical education, and clinical trials.
From the Journals
Hepatitis screening now for all patients with cancer on therapy
All patients with cancer who are candidates for systemic therapy should be screened for hepatitis B, says the American Society of Clinical...
From the Journals
Early screening may halve breast cancer mortality in childhood cancer survivors
A modeling study supports early breast cancer screening in women with a history of chest radiation.
From the Journals
Eczema may increase lymphoma risk, cohort studies suggest
For severe eczema, the adjusted hazard ratio for non-Hodgkin lymphoma was 2.08.
Conference Coverage
Safe to skip radiotherapy with negative PET in Hodgkin lymphoma
“Most patients with this disease will not need radiotherapy any longer,” concluded Dr. Peter Borchmann.
From the Journals
Cancer risk elevated in hidradenitis suppurativa patients
Overall cancer risk and risk of several specific cancers was significantly higher among adults with hidradenitis suppurativa compared with...
Conference Coverage
Pembrolizumab prolonged PFS vs. brentuximab vedotin in r/r Hodgkin lymphoma
Pembrolizumab should be considered “the preferred treatment option and the standard of care” for patients with classic Hodgkin lymphoma not...
Conference Coverage
20% with cancer on checkpoint inhibitors get thyroid dysfunction
Researchers report more than double the rate of hypothyroidism and more than triple the rate of hyperthyroidism, compared with rates in published...